Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immunome, Inc. stock logo
IMNM
Immunome
$9.86
-1.0%
$9.74
$5.15
$16.73
$856.39M1.93991,990 shs237,455 shs
uniQure N.V. stock logo
QURE
uniQure
$16.26
+3.3%
$14.60
$4.45
$19.18
$890.77M0.111.36 million shs891,740 shs
Acelyrin, Inc. stock logo
SLRN
Acelyrin
$2.27
$2.27
$1.85
$7.10
$229.17M1.071.29 million shsN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
$19.32
-1.1%
$16.80
$3.42
$21.01
$890.81M1.121.53 million shs664,786 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immunome, Inc. stock logo
IMNM
Immunome
-2.07%+3.97%-8.21%+11.17%-33.53%
uniQure N.V. stock logo
QURE
uniQure
-0.25%+1.74%+5.14%+5.70%+159.05%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
0.00%0.00%0.00%0.00%-54.96%
Urogen Pharma stock logo
URGN
Urogen Pharma
+0.21%+1.19%+3.39%+392.19%+36.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Immunome, Inc. stock logo
IMNM
Immunome
1.587 of 5 stars
3.50.00.00.02.02.50.0
uniQure N.V. stock logo
QURE
uniQure
2.4161 of 5 stars
3.51.00.00.02.62.50.6
Acelyrin, Inc. stock logo
SLRN
Acelyrin
2.0801 of 5 stars
3.20.00.00.00.62.51.3
Urogen Pharma stock logo
URGN
Urogen Pharma
4.4853 of 5 stars
4.53.00.04.51.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immunome, Inc. stock logo
IMNM
Immunome
3.00
Buy$22.50128.31% Upside
uniQure N.V. stock logo
QURE
uniQure
3.00
Buy$37.45130.31% Upside
Acelyrin, Inc. stock logo
SLRN
Acelyrin
2.33
Hold$7.33223.05% Upside
Urogen Pharma stock logo
URGN
Urogen Pharma
3.00
Buy$32.0065.63% Upside

Current Analyst Ratings Breakdown

Latest SLRN, URGN, IMNM, and QURE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/25/2025
Immunome, Inc. stock logo
IMNM
Immunome
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
8/22/2025
Immunome, Inc. stock logo
IMNM
Immunome
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$18.00
8/18/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$36.00
8/14/2025
uniQure N.V. stock logo
QURE
uniQure
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$30.00
8/11/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $40.00
8/7/2025
Immunome, Inc. stock logo
IMNM
Immunome
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$23.00 ➝ $22.00
8/7/2025
Immunome, Inc. stock logo
IMNM
Immunome
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$21.00
8/5/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/30/2025
uniQure N.V. stock logo
QURE
uniQure
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$47.00
7/29/2025
uniQure N.V. stock logo
QURE
uniQure
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $35.00
7/8/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immunome, Inc. stock logo
IMNM
Immunome
$9.04M94.89N/AN/A$3.09 per share3.19
uniQure N.V. stock logo
QURE
uniQure
$14.34M62.24N/AN/A($0.07) per share-232.33
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/AN/AN/AN/A$6.74 per shareN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
$91.87M9.73N/AN/A($2.02) per share-9.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immunome, Inc. stock logo
IMNM
Immunome
-$292.96M-$3.08N/AN/AN/A-1,687.08%-76.10%-65.14%11/12/2025 (Estimated)
uniQure N.V. stock logo
QURE
uniQure
-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%11/4/2025 (Estimated)
Acelyrin, Inc. stock logo
SLRN
Acelyrin
-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
-$126.87M-$3.32N/AN/AN/A-164.44%-97,487.15%-59.38%11/5/2025 (Estimated)

Latest SLRN, URGN, IMNM, and QURE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.82-$1.05-$0.23-$1.05$23.06 million$24.22 million
8/6/2025Q2 2025
Immunome, Inc. stock logo
IMNM
Immunome
-$0.52-$0.50+$0.02-$0.50$1.03 million$4.02 million
7/29/2025Q2 2025
uniQure N.V. stock logo
QURE
uniQure
-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immunome, Inc. stock logo
IMNM
Immunome
N/A
12.13
12.13
uniQure N.V. stock logo
QURE
uniQure
1.53
9.98
9.98
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/A
7.15
7.15
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
4.14
3.99

Institutional Ownership

CompanyInstitutional Ownership
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
uniQure N.V. stock logo
QURE
uniQure
78.83%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
87.31%
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%

Insider Ownership

CompanyInsider Ownership
Immunome, Inc. stock logo
IMNM
Immunome
7.69%
uniQure N.V. stock logo
QURE
uniQure
4.79%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
13.60%
Urogen Pharma stock logo
URGN
Urogen Pharma
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immunome, Inc. stock logo
IMNM
Immunome
4087.04 million80.35 millionOptionable
uniQure N.V. stock logo
QURE
uniQure
50054.87 million52.24 millionOptionable
Acelyrin, Inc. stock logo
SLRN
Acelyrin
135100.95 million86.68 millionOptionable
Urogen Pharma stock logo
URGN
Urogen Pharma
20046.26 million44.09 millionOptionable

Recent News About These Companies

UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma: Targeting Profits In 2027

New MarketBeat Followers Over Time

Media Sentiment Over Time

Immunome stock logo

Immunome NASDAQ:IMNM

$9.86 -0.10 (-0.95%)
As of 03:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

uniQure stock logo

uniQure NASDAQ:QURE

$16.26 +0.51 (+3.26%)
As of 03:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Acelyrin stock logo

Acelyrin NASDAQ:SLRN

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$19.32 -0.22 (-1.13%)
As of 03:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.